Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: Post-hoc, subgroup analyses of data from the SANAD trial

The Lancet Neurology

Volumn 11, Issue 4, 2012, Pages 331-340

  Bonnett, Laura ^a   Smith, Catrin Tudur ^a   Smith, David ^b   Williamson, Paula ^a   Chadwick, David ^b   Marson, Anthony G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; TOPIRAMATE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DRUG TREATMENT FAILURE; ELECTROENCEPHALOGRAM; FEMALE; FOCAL EPILEPSY; FRONTAL LOBE EPILEPSY; GENDER; GENERALIZED EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SCHOOL CHILD; TEMPORAL LOBE EPILEPSY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AMINES; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE-FREE SURVIVAL; EPILEPSIES, PARTIAL; FEMALE; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT FAILURE; TRIAZINES; YOUNG ADULT;

EID: 84862797735     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70018-2     Document Type: Article

References (29)

1. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1000-1015.
2. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010, 51:676-685.
3. Engel JJ ILAE classification of epilepsy syndromes. Epilepsy Res 2006, 70(suppl 1):5-10.
4. Cockerell OC, Sander JWAS, Hart YM, Shorvon SD, Johnson AL Remission of epilepsy: results from the National General-Practice Study of Epilepsy. Lancet 1995, 346:140-144.
5. Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet 1991, 337:1175-1180. Medical Research Council Antiepileptic Drug Withdrawal Study Group.
6. Marson A, Jacoby A, Johnson A, Kim L, Gamble C, Chadwick D Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 2005, 365:2007-2013. on behalf of the Medical Research Council MESS Study Group.
7. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1016-1026.
8. Guidelines for Good Clinical Practice in Clinical Trials 1998, Medical Research Council, Medical Research Council, London.
9. Kim LG, Johnson TL, Marson AG, Chadwick DW Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol 2006, 5:317-322.
10. MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JWAS, Shorvon SD Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000, 48:833-841.
11. Kraemer HC, Blasey CM Centring in regression analyses: a strategy to prevent errors in statistical inference. Int J Methods Psychiatr Res 2004, 13:141-151.
12. Collett D Modelling Survival Data in Medical Research 2003, Chapman & Hall/CRC, Boca Raton.
13. Schoenfeld D Partial residuals for the proportional hazards regression-model. Biometrika 1982, 69:239-241.
14. Harrell FE, Lee KL, Mark DB Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15:361-387.
15. Gray RJ A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
16. Royston P, Ambler G, Sauerbrei W The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999, 28:964-974.
17. Royston P, Altman DG Regression using fractional polynomials of continuous covariates-parsimonious parametric modeling. J R Stat Soc Ser C Appl Stat 1994, 43:429-467.
18. Royston P, Sauerbrei W Multivariable Model-Building-a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables 2008, Wiley, Chichester.
19. Royston P, Sauerbrei W Building multivariable regression models with continuous covariates in clinical epidemiology-with an emphasis on fractional polynomials. Methods Inf Med 2005, 44:561-571.
20. Stone CJ Comment: generalized additive models. Stat Sci 1986, 1:3.
21. Royston P, Sauerbrei W Improving the robustness of fractional polynomial models by preliminary covariate transformation: a pragmatic approach. Comput Stat Data Anal 2007, 51:4240-4253.
22. Hosmer DW, Lemeshow S Applied Logistic Regression 2000, John Wiley & Sons, New York. 2nd edn.
23. Harrell FE Regression modeling stategies: with applications to linear models, logistic regression, and survival analysis 2001, Springer, New York.
24. Bonnett LJ, Tudur-Smith C, Williamson PR, Marson AG Risk of recurrence after a first seizure and implications for driving: further analysis of the Multicentre study of early Epilepsy and Single Seizures. BMJ 2010, 341:c6477.
25. Bonnett LJ, Shukralla A, Tudur-Smith C, Williamson PR, Marson AG Seizure recurrence after antiepileptic drug withdrawal and the implications for driving: further results from the MRC Antiepileptic Drug Withdrawal Study and a systematic review. J Neurol Neurosurg Psychiatry 2011, 82:1328-1333.
26. Panayiotopoulos CP Old versus new antiepileptic drugs: the SANAD study. Lancet 2007, 370:313-314.
27. Panayiotopoulos CP Evidence-based epileptology, randomized controlled trials, and SANAD: a critical clinical view. Epilepsia 2007, 48:1268-1274.
28. Tudur Smith C, Marson A, Chadwick D, Williamson P Multiple treatment comparisons in epilepsy monotherapy trials. Trials 2007, 8:34.
29. *3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011, 364:1134-1143.